免疫系统
肾细胞癌
癌症研究
肿瘤微环境
疾病
生物
谷氨酰胺
代谢途径
重编程
细胞
生物信息学
医学
线粒体
免疫疗法
脂质代谢
癌症
代谢组学
肾透明细胞癌
肿瘤细胞
新陈代谢
细胞代谢
肾癌
细胞代谢
免疫学
机制(生物学)
转录组
免疫监视
信号转导
癌
诊断生物标志物
肾
免疫检查点
作者
Giuseppe Tiziano Lucarelli,Monica Rutigliano,Martina Milella,Alessandro Caniglia,Pasquale Ditonno,Francesco M. Lasorsa
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2026-11-10
卷期号:18 (22): 3600-3600
标识
DOI:10.3390/cancers18223600
摘要
Renal cell carcinoma (RCC) is increasingly recognized as a metabolic disease driven by genetic alterations that regulate cellular energetics. In clear cell RCC (ccRCC), loss of the von Hippel-Lindau (VHL) gene stabilizes hypoxia-inducible factors (HIFs), promoting a pseudo-hypoxic state that enhances glycolysis, suppresses mitochondrial oxidation, and remodels lipid metabolism. Here we review how these metabolic reprogramming events, including glutamine dependence and oncometabolite accumulation in rarer subtypes, reshape the tumor microenvironment and contribute to immune evasion. We highlight recent advances in targeting these pathways, notably the clinical success of the HIF-2α inhibitor belzutifan, alongside emerging metabolic biomarkers and imaging modalities. These insights underscore the potential of metabolism-based strategies to improve RCC diagnosis and therapy while emphasizing the complex interplay between tumor metabolism and immune regulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI